Here’s something most pharma HEOR teams don’t admit publicly: they’re spending 60-80% of their time fighting data access battles instead of generating the evidence that actually matters for market access.
I’ve watched countless pharmaceutical companies struggle with the same painful cycle. They need robust real-world evidence for their HTA submissions and payer negotiations. But by the time they navigate the privacy regulations, execute the data use agreements, and wait for claims data that’s already 12-18 months old… their launch window has narrowed, competitors have moved, and payers are asking questions they can’t answer quickly enough.
The good news? There’s a fundamentally different approach emerging—one that replaces these traditional bottlenecks with immediate access to privacy-compliant, analysis-ready datasets.
Why Traditional Health Insurance Data Creates HEOR Bottlenecks
The challenges with conventional claims and EMR data aren’t just inconvenient. They’re strategically dangerous for pharmaceutical manufacturers trying to demonstrate value in increasingly skeptical payer environments.
Most HEOR teams face three interconnected problems that compound each other:
Privacy regulations have become a labyrinth. GDPR Article 9 restrictions on special category health data mean that accessing real patient-level information requires extensive legal review, data use agreements that can take 4-6 months to negotiate, and ongoing compliance monitoring that diverts resources from actual analysis. And that’s before you even touch the data.
Then there’s the fragmentation problem. Your health insurance cost data lives in claims databases. Your clinical outcomes and treatment details are trapped in EMR systems. Hospital resource utilization sits in separate DRG databases. Creating a complete longitudinal patient journey—the kind that shows how patients actually move through the healthcare system and respond to treatments over time—becomes a massive data engineering project requiring specialized linkage algorithms and months of harmonization work.
The timing issue makes everything worse. By the time you access traditional claims cost databases and healthcare utilization data, it’s often 12-18 months behind current market reality. For a pharmaceutical launch or a competitive response to generic entry, that lag can mean the difference between a successful market access strategy and a pricing disaster.
What Modern HEOR Strategy Actually Requires
Here’s what I’ve learned from working with pharma HEOR strategy teams across dozens of submissions: the evidence generation landscape has fundamentally shifted.
Health technology assessment bodies and payers aren’t just asking for clinical trial results anymore. They want proof of real-world cost-effectiveness. They need budget impact models populated with actual resource utilization data from their markets. They’re demanding comparative effectiveness evidence against current standard of care—evidence that’s nearly impossible to generate from traditional RCTs alone.
According to Makady et al. (2017) in their comparative study of six HTA agencies, real-world evidence now plays a central role in health technology assessment across major markets. The agencies explicitly seek RWE to address gaps in clinical trial evidence, understand treatment patterns in routine practice, and validate long-term outcomes.
But—and this is critical—they need this evidence fast, and they need it to be methodologically sound.
That’s where the traditional approach breaks down completely.
The Synthetic Health Insurance Data Revolution
Synthetic health insurance data represents a fundamental rethinking of how we approach HEOR data sourcing. And no, this isn’t about “fake” data or statistical tricks.
Think of it this way: synthetic datasets are statistically identical replicas of real patient populations—they preserve all the complex relationships, cost patterns, comorbidity correlations, and treatment sequences from actual claims data—but contain zero identifiable patient information. Not pseudonymized. Not anonymized through aggregation. Actually synthetic, generated through advanced techniques like Generative Adversarial Networks.
As Goncalves et al. (2020) demonstrate in their comprehensive methodology review, properly generated synthetic patient data maintains statistical fidelity while eliminating privacy concerns entirely. Their validation framework shows that synthetic cohorts can reproduce complex clinical and economic patterns with remarkable accuracy.
What does this actually mean for your HEOR studies?
Immediate access. No DUAs. No IRB approvals for retrospective analyses. No compliance reviews that stretch for months. You’re working with data that’s privacy-compliant by design, which means you can start your cost-effectiveness modeling or budget impact analysis the same week you identify the strategic need.
Perfect for scenario modeling. Here’s something you absolutely cannot do with real patient data: model hypothetical care pathways or pricing strategies. With synthetic health insurance data for HEOR, you can test “what-if” scenarios—what happens if treatment sequencing changes? What’s the budget impact under different reimbursement models? How do cost burdens shift if we adjust indication criteria?
Shareable across borders. Your global HEOR team can access the same synthetic datasets without running into cross-border data transfer restrictions. Your CRO partners can work with the data. Your health economics consultancy can validate your models. No special agreements needed.
Why Claims and EMR Linked Datasets Change Everything
But synthetic data alone isn’t the complete answer for pharma HEOR. The real transformation happens when you combine synthetic health insurance data with linked electronic medical records.
Here’s the challenge most pharmaceutical manufacturers face with traditional data: claims tell you what was billed and how much it cost, but not why. EMRs tell you clinical details—lab values, vital signs, physician notes—but lack the complete cost picture and healthcare utilization patterns across the entire care continuum.
Claims and EMR linked datasets for HEOR solve this by creating a unified view of the patient journey. You see the clinical rationale for treatment decisions (from EMR), the actual costs and resource utilization (from claims), and how patients move through different care settings over time (from both sources combined).
Casey et al. (2016) provide an excellent review of methods for using electronic health records in population health research. Their work highlights how linked datasets enable researchers to examine treatment effectiveness, safety profiles, and economic outcomes simultaneously—exactly what payer analytics require.
For HEOR modeling, this integration is transformative:
Your economic evaluation datasets now include both cost inputs (from claims) and clinical effectiveness measures (from EMR). You’re not making assumptions about clinical outcomes based on trial data alone—you’re seeing what actually happened in real-world patient cohorts who received the treatment.
Your burden of illness data becomes multidimensional. You can quantify not just the direct medical costs from claims cost database sources, but also relate them to disease severity markers, complications, and progression patterns visible in the clinical record.
Treatment utilization datasets reveal the complete picture. You see not just that a patient received a medication (from pharmacy claims), but their concomitant medications, comorbidities, lab monitoring, and outcomes—all connected in longitudinal health datasets for HEOR.
Building Longitudinal Patient Cohorts That Actually Answer Strategic Questions
Most pharmaceutical companies underestimate how much strategic value lives in longitudinal cohort analysis. They think about HEOR data sources as a one-time extraction for a specific study.
That’s a mistake.
Longitudinal health datasets for HEOR—properly constructed patient cohorts followed over months or years—are your competitive intelligence goldmine. They show you things that cross-sectional analyses simply cannot reveal.
Real-world patient cohorts for HEOR let you track treatment persistence and switching patterns over time. How long do patients actually stay on therapy in routine practice? When they discontinue, what do they switch to? What clinical or cost factors predict persistence? These aren’t academic questions—they directly inform your market access datasets for HEOR strategy and your positioning against competitors.
Herrett et al. (2015) profile the Clinical Practice Research Datalink, one of the world’s most respected linked databases. Their description of longitudinal capabilities—tracking patients from diagnosis through multiple treatment lines to outcomes—demonstrates the gold standard that modern HEOR datasets should aspire to match.
Disease progression modeling becomes evidence-based rather than assumption-based. Instead of guessing at progression rates from limited trial follow-up, you observe actual disease trajectories in thousands of patients over years. Your Markov models and state-transition assumptions are grounded in real-world data, making your health outcomes datasets far more credible to skeptical payers.
Healthcare resource utilization patterns emerge clearly. You can quantify not just drug costs, but the complete cost burden—hospitalizations, ER visits, specialist consultations, diagnostic procedures. Your healthcare resource utilization database queries reveal which patient segments drive costs, when costs spike during the disease journey, and how your treatment affects the total cost of care.
Privacy-Compliant HEOR Datasets: More Than a Checkbox
I need to be direct about something that often gets glossed over in HEOR data discussions: privacy compliance isn’t just about avoiding legal problems. It’s about operational speed and strategic flexibility.
Every pharmaceutical manufacturer I’ve worked with has experienced the pain of a stalled study because of data governance concerns. Your medical affairs team needs post-authorization observational study data. But legal counsel needs three months to review the data use agreement. Compliance wants an external audit. And by the time you have access, your competitor has already published their real-world effectiveness evidence.
Privacy-compliant HEOR datasets—particularly synthetic health insurance data and properly anonymized aggregate data—eliminate this entire bottleneck. You’re working with data that’s compliant by design, not compliant through restrictions and oversight.
GDPR Article 9 doesn’t apply to properly synthetic data because it contains no personal information to protect. You don’t need patient consent for synthetic cohorts. Data Protection Impact Assessments become straightforward. Cross-border transfers are unrestricted.
The strategic implication? Your HEOR rwe analytics can move at the speed of business decisions, not at the speed of legal review.
RWE Platform for HEOR Studies: From Data to Actionable Insights
Having access to high-quality datasets is necessary but not sufficient. The next bottleneck most pharma HEOR teams hit is the analysis infrastructure challenge.
A modern RWE platform for HEOR studies does something fundamentally different from traditional data warehouses: it’s designed from the ground up for health economics and outcomes research use cases, not generic business intelligence.
That means pre-built cohort identification tools that understand clinical inclusion/exclusion criteria. Automated cost aggregation that knows how to handle different cost perspectives (payer vs. societal vs. healthcare system). Built-in statistical methods for comparative effectiveness—propensity score matching, inverse probability weighting, instrumental variables—that epidemiologists need but data engineers don’t typically implement.
Schneeweiss (2014) captures this perfectly in his NEJM perspective on learning from big healthcare data. He emphasizes that the value isn’t in data volume—it’s in the ability to rapidly generate valid, actionable insights through appropriate methodology and domain expertise embedded in analytical workflows.
For pharmaceutical manufacturers, this translates to concrete advantages:
Your health economics datasets become queryable by your HEOR analysts directly—not requiring weeks of data scientist support for every analysis. The platform handles the data engineering, the schema complexity, the longitudinal linkages. Your team focuses on the research questions that inform pharma HEOR strategy.
Your RWE analytics for HEOR are reproducible and transparent. When payers or regulators question your methodology, you can show them exactly how cohorts were defined, how costs were calculated, how confounding was addressed. The audit trail is built in.
Your economic evaluation datasets feed directly into modeling tools. Need to populate a budget impact model with real-world cost and utilization parameters? Export directly from the RWE platform with the stratifications and time horizons your model requires.
Supporting Economic Evaluation and Cost-Effectiveness Modeling
This is where everything converges into demonstrable value for market access teams.
Cost-effectiveness modeling—the core of most HTA submissions—depends entirely on the quality and relevance of your input parameters. Garbage in, garbage out, as the saying goes. But the challenge is deeper than data quality. It’s about having the right data structure and granularity for the specific health economics methodology you’re applying.
Garrison et al. (2018) provide the ISPOR task force guidance on measuring drug costs for cost-effectiveness analyses. Their framework makes clear that robust cost modeling databases require not just average costs, but the ability to examine cost distributions, identify high-cost subgroups, and understand variability across patient characteristics and care settings.
Healthcare outcomes databases that combine synthetic health insurance data with EMR-linked clinical outcomes enable this level of sophistication.
For a budget impact model, you need baseline disease prevalence, current treatment mix, costs by treatment pathway, and projected market shares. With traditional data approaches, you’re cobbling together these parameters from disparate published sources with different reference years and populations. With integrated health economics statistics database access, you’re extracting all parameters from a single, coherent patient population with consistent definitions.
For cost-utility analysis and QALY calculations, you need health state utilities mapped to observable clinical states. Longitudinal health datasets let you track patients through health states over time, observe transitions, and estimate state-specific costs and outcomes. Your model structure can reflect the actual complexity of disease progression rather than being forced into simplistic assumptions because of data limitations.
Neumann and Cohen (2018) discuss the advantages and concerns around QALYs as the central metric in cost-effectiveness analysis. Their perspective reinforces that credible QALY estimation requires robust real-world data on health state durations and utilities—exactly what longitudinal patient cohorts provide.
Outcomes Research and Evidence Generation for Payer Negotiations
The evidence that wins payer negotiations isn’t the prettiest or most sophisticated analytically. It’s the evidence that directly answers the specific objections and questions payers actually have about your product.
Payers want to know: How does your treatment perform in patients like mine—older, sicker, with more comorbidities than your trial population? What’s the real-world effectiveness when adherence isn’t perfect? How does cost burden compare across the full episode of care, not just drug acquisition?
Outcomes research datasets built from claims and EMR linked data let you address these questions with observational study data for HEOR that reflects the messiness of actual clinical practice.
Berger et al. (2017) provide the joint ISPOR-ISPE task force recommendations for good practices in RWE studies of treatment and comparative effectiveness. Their framework emphasizes transparency in study design, appropriate handling of confounding, and validation of findings—all critical for generating evidence that payers will trust.
Real-world treatment utilization datasets reveal adherence patterns that clinical trials hide. Your HEOR analysis can show that while efficacy may be slightly lower in routine practice than in trials (expected), the safety profile is actually better because exclusion criteria don’t artificially screen out the real patient population.
Disease burden datasets contextualize your treatment’s value. By quantifying the complete cost of illness—direct medical, indirect productivity, caregiver burden—you shift the conversation from drug cost in isolation to impact on total disease management cost.
Comparative effectiveness becomes possible even when head-to-head trials don’t exist. Using sophisticated causal inference methods on real-world patient cohorts, you can generate adjusted comparisons that payers find credible for formulary decisions.
From Cost Modeling to Market Access Strategy: The Integration Challenge
Here’s something that frustrates me about how pharmaceutical manufacturers often approach HEOR: they treat it as a technical exercise divorced from commercial strategy.
Your Director of Commercial Analytics is forecasting based on one set of assumptions about market size and treatment flow. Your Market Access team is negotiating with payers using different prevalence numbers and cost offsets. Your HEOR team is building models with yet another set of parameters.
Everyone’s working hard. Nobody’s working from the same integrated pharma heor data foundation.
The most successful pharma heor strategy implementations I’ve seen integrate pricing and reimbursement datasets directly into strategic planning workflows. Market access datasets for HEOR aren’t just for submissions—they’re informing launch sequencing, indication prioritization, and pricing strategy from the beginning.
Kantarjian and Rajkumar (2015) discuss drug pricing pressures in various markets. While focused on oncology, their analysis applies broadly: the growing demand for value demonstration has made robust health economics consultancy support and comprehensive HEOR services essential for pharmaceutical manufacturers, not optional.
This means your payer analytics database needs to be accessible not just to HEOR analysts but to commercial teams asking market access questions. What’s our market opportunity in patient segments where we have the strongest health economics story? Which therapeutic areas have the most favorable cost-effectiveness landscape? Where are competitors vulnerable on outcomes evidence?
Synthetic health insurance data enables this integration because it’s shareable across teams without privacy restrictions. Your HEOR modeling and commercial analytics can literally work from the same patient cohorts, ensuring alignment.
Navigating the Data Partnership Landscape: What to Look For
The challenge many pharmaceutical companies face isn’t finding data sources—it’s determining which combination of capabilities aligns with their strategic priorities.
The real-world data market has evolved into a complex ecosystem with dozens of providers offering overlapping but distinct capabilities. Understanding which approach matches your specific needs requires evaluating providers across several critical dimensions:
Coverage breadth and depth. Some providers maintain comprehensive longitudinal records covering hundreds of millions of patient lives across multiple regions and payer types. Others focus on specific geographies or populations with greater clinical depth. The question isn’t which is “better”—it’s which coverage profile matches your therapeutic areas and target markets.
Data recency and refresh cycles. Real-time data access enables rapid competitive intelligence and launch monitoring. Adjudicated claims data, while lagged by 6-18 months, offers greater billing accuracy and completeness. Your use case determines which trade-off makes sense—forecasting models need different timeliness than retrospective burden-of-illness studies.
Analytical sophistication. Capabilities range from traditional query-based systems to AI-powered platforms offering real-time pattern recognition and predictive analytics. Some providers offer self-service tools for internal teams, while others provide full-service analytical support. The choice depends on whether you need descriptive intelligence or forward-looking insights, and whether you have the internal analytical capacity to execute independently.
Data integration and linkages. Some sources combine claims with complementary data—lab results, specialty pharmacy, EMR extracts, social determinants of health—for richer patient profiles. This vertical integration creates analytical possibilities that pure claims data cannot support. But it also increases complexity and cost. Understanding which data combinations your use cases actually require prevents over-purchasing.
Cost models and licensing structures. Pricing varies dramatically based on access model (one-time project vs. ongoing license), data scope (therapeutic area subset vs. full database), user count, and analytical support level. Some providers charge by patient count, others by user seat, others by query volume. Aligning the cost structure with your usage patterns is critical for ROI.
The gap between understanding what claims data can theoretically enable and identifying which specific provider combination matches your needs is substantial. This is where expert guidance becomes critical—navigating this landscape requires deep market knowledge that most pharmaceutical companies lack internally.
The Technical Requirements Nobody Talks About (But Everyone Struggles With)
I want to be honest about something that marketing materials often gloss over: implementing a sophisticated HEOR data and analytics capability is technically demanding.
You need analysts who understand both healthcare data structures and health economics methodology. Your team needs to be fluent in ICD-10 coding, ATC classification, DRG systems, and also understand Markov modeling, survival analysis, and causal inference. That’s a rare combination.
The data science requirement is real. Even with an RWE analytics for HEOR platform that handles the infrastructure, you still need people who can validate synthetic data quality, understand the limitations of different data sources, and translate complex technical outputs into evidence that payers will accept.
Chen et al. (2021) provide a comprehensive narrative review of synthetic data in healthcare, including an honest assessment of challenges. Synthetic data isn’t magic—it requires validation against real-world benchmarks, understanding of the generative methodology’s limitations, and transparency about what the data can and cannot support.
For pharmaceutical manufacturers evaluating heor data sources, here’s what to validate:
Statistical fidelity. How closely do distributions, correlations, and clinical patterns in synthetic datasets match the underlying real population? You need validation reports comparing key metrics.
Clinical face validity. Do treatment sequences make sense? Are comorbidity patterns realistic? Would a practicing physician recognize these patient journeys as plausible?
Temporal consistency. Longitudinal patterns—disease progression, treatment switching, healthcare utilization trajectories—should reflect actual clinical realities, not artifacts of the synthetic generation process.
Subgroup representation. Are rare conditions, special populations, and edge cases properly represented? Or has the synthesis process smoothed out important clinical variation?
Implementation Realities: What Actually Works in Pharma Organizations
Based on working with dozens of pharmaceutical companies implementing new HEOR data capabilities, I can tell you what separates successful implementations from those that stall or underdeliver.
Start with a clear use case, not a general capability. “We need better HEOR data” is too broad. “We need to build a budget impact model for our NASH asset’s launch with regional payer cost inputs” is specific enough to design around. You’ll build broader capabilities over time, but starting focused prevents analysis paralysis.
Integrate early with your market access timeline. The biggest waste I see is pharmaceutical manufacturers who invest in comprehensive health economics datasets but only engage their HEOR team six months before filing. By then, you’re rushed, you can’t do the methodologically sophisticated analyses that would differentiate your dossier, and you end up defaulting to conservative assumptions that undervalue your product.
Build internal analytical literacy. Even with the best RWE platform for HEOR studies and expert analytical support, your teams need to understand the fundamentals. What’s the difference between observational study data and experimental data? When is propensity score matching appropriate? How do you interpret real-world utilization data when prescribing patterns are changing?
Drummond et al. (2015) outline key principles for improved HTA conduct. Their emphasis on transparency, stakeholder engagement, and methodological rigor underscores why pharmaceutical manufacturers need sophisticated internal capabilities, not just outsourced analyses.
Leverage expert guidance for data partnership selection. The claims data landscape is complex, with dozens of providers offering overlapping but distinct capabilities. Understanding which combination of coverage, analytical tools, and domain expertise matches your specific needs requires deep market knowledge. Expert advisors who understand both your business objectives and the evolving real-world evidence ecosystem can accelerate your path to value while avoiding costly mismatches.
Prioritize transparency over complexity. Payers increasingly want to see your data and methods, not just your results. A simpler analysis with transparent methodology and accessible data sources will be more credible than a black-box sophisticated model, even if the latter is technically superior.
The Strategic Shift: From Cost Center to Competitive Advantage
One more thing I’ve observed about how pharmaceutical companies approach HEOR: they often position it as a necessary regulatory compliance function rather than a source of competitive advantage.
That’s leaving value on the table.
When you have superior health insurance cost data, more comprehensive treatment utilization datasets, and faster access to insights than your competitors, that’s not just about meeting payer evidence requirements. It’s about shaping the conversation.
You can proactively publish real-world evidence before competitors, establishing the evidentiary standard for the therapeutic area. You can identify underserved patient segments where your product’s value proposition is strongest and focus your market access strategy there. You can respond to competitor claims with data-driven counterpositioning within weeks instead of quarters.
Neumann and Cohen (2018) note that health economics evidence increasingly shapes not just reimbursement decisions but also prescriber perceptions and clinical guideline development. Having a robust HEOR evidence generation capability is becoming table stakes for competitive positioning.
This strategic perspective changes how you evaluate investments in pharma heor data infrastructure. The question isn’t “what’s the cost of comprehensive health economics statistics database access?” It’s “what’s the revenue impact of launching three months earlier with stronger payer evidence? What’s the pricing power gained from demonstrating superior cost-effectiveness? What’s the market share protection from having published real-world outcomes data when competitors enter?”
Getting Started: A Practical Framework
If you’re a pharmaceutical manufacturer looking to upgrade your HEOR data and analytics capabilities, here’s a practical framework I’ve seen work:
Phase 1: Strategic Assessment (Month 1)
Map your critical evidence gaps across your pipeline and marketed products. Where are payers pushing back? Which HTA submissions need stronger real-world evidence? What market access questions can’t you answer quickly today?
Identify your priority therapeutic areas and geographies. You don’t need comprehensive coverage everywhere immediately. Target where the commercial impact is highest.
Evaluate your internal analytical capabilities honestly. Do you have the HEOR analyst capacity? The data science skills? The epidemiology expertise? Understanding gaps now prevents implementation delays later.
Phase 2: Requirements Definition and Landscape Assessment (Month 2-3)
Before evaluating specific data providers, define your requirements clearly. Document your coverage needs (geographies, therapeutic areas, patient populations), analytical capabilities (self-service vs. full-service), integration requirements (API access, data formats), compliance constraints, and budget parameters. This clarity prevents costly mismatches.
Understand the landscape dimensions. The real-world data market includes dozens of providers with overlapping but distinct capabilities. Key dimensions include data recency (real-time vs. adjudicated), geographic coverage, therapeutic depth, analytical tools, and cost models. Expert consultants can help structure this requirements definition process to ensure you’re comparing options on the dimensions that actually matter for your use cases.
Prioritize data sources that offer immediate analysis readiness. Solutions that require six months of data engineering defeat the purpose of investing in external data.
Phase 3: Pilot Implementation (Month 4-6)
Start with one high-value use case. Prove out the workflow, validate the data quality, demonstrate the time-to-insight improvement.
Build your first real market access dataset output—a budget impact model, a comparative effectiveness analysis, a disease burden study. Use it in an actual submission or payer meeting.
Document lessons learned. What worked? What took longer than expected? What additional data or analytical support do you need?
Phase 4: Scale and Integration (Month 7+)
Expand to additional therapeutic areas and use cases based on pilot learnings.
Integrate health economics datasets into your standard market access workflow. Make RWE analytics for HEOR a routine part of asset planning, not a special project.
Build feedback loops between commercial analytics, HEOR, and medical affairs. Let real-world evidence inform forecasting. Let market access insights shape clinical development strategy.
The Future of HEOR in Pharma: What’s Coming Next
The HEOR data landscape is evolving rapidly, and pharmaceutical manufacturers need to understand where things are heading.
Synthetic data generation is becoming more sophisticated. Next-generation approaches using transformer models and diffusion techniques promise even higher fidelity for rare events and complex patient journeys. The privacy guarantees are getting stronger through differential privacy methods that can be mathematically proven.
Walonoski et al. (2018) describe Synthea, a major open-source synthetic patient generation engine. While focused on methodology, their work hints at the future: synthetic data that’s not just statistically similar but causally coherent, enabling counterfactual reasoning about treatment effects.
Real-world data infrastructure is becoming more real-time. The lag between clinical events and data availability is shrinking. Partnerships between data providers and health systems are enabling near-real-time observational research on treatment utilization datasets.
Analytical methods are advancing. Machine learning approaches to causal inference, automated confounding detection, and synthetic control methods are making it easier to generate robust comparative effectiveness evidence from observational study data for HEOR.
Regulatory acceptance is crystallizing. EMA guidelines on real-world evidence are becoming more specific. Regulatory agencies are publishing more framework documents. The methodological debates are settling, and best practices are emerging. For pharmaceutical manufacturers, this means clearer standards for what types of heor real world data analyses will be accepted in submissions.
The question isn’t whether real-world evidence will be central to pharmaceutical market access—that’s already happening. The question is whether your organization will have the data infrastructure and analytical capabilities to compete effectively in this environment.
Your Next Steps: Building Competitive HEOR Capability
The pharmaceutical companies succeeding in today’s payer environment share a common characteristic: they’ve moved beyond treating HEOR as a compliance exercise and transformed it into a core strategic capability.
That transformation requires three foundational elements:
First, access to privacy-compliant heor datasets that combine breadth of coverage, depth of clinical and economic detail, and speed of access. Synthetic health insurance data for HEOR provides that foundation, especially when linked with EMR data to create comprehensive longitudinal patient cohorts.
Second, an RWE platform for HEOR studies that translates data into insights without requiring months of data engineering for every analysis. Your HEOR analysts should be answering strategic questions, not wrestling with data infrastructure.
Third, integration into your market access workflow from day one. Health economics datasets aren’t just for submissions—they should inform your launch strategy, pricing decisions, indication sequencing, and competitive positioning throughout your asset’s lifecycle.
The cost of inaction is measurable. Every delayed launch, every pricing concession from weak evidence, every lost market share from inferior payer positioning—these have quantifiable revenue impacts that dwarf the investment in robust HEOR data infrastructure.
Understanding what types of claims data exist and what questions they can answer is the first step. The second step—matching your requirements to the right combination of data sources, analytical capabilities, and domain expertise—requires guidance from professionals who understand both the pharmaceutical industry and the evolving real-world evidence ecosystem.
Ready to explore how synthetic health insurance data and advanced RWE analytics can transform your market access strategy? Discover our specialized approach to real-world intelligence and learn how expert navigation of the data landscape can accelerate your path to value.
For a detailed look at how synthetic data methodologies work and their validation standards, see our previous article on aggregated synthetic insurance data for pharmaceutical applications.
Want to understand how simulation approaches can accelerate your HEOR modeling? Our next article covers HEOR simulation using aggregated data for scenario planning.
Contact us to discuss your specific data requirements and explore strategic approaches to real-world intelligence that align with your business objectives. We help pharmaceutical manufacturers navigate the complex landscape of HEOR data partnerships, ensuring you find the right combination of capabilities without the costly trial-and-error most companies experience.
Sources & References
- Berger, M. L., et al. (2017). “Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.” Value in Health, 20(8), 1003-1008. https://www.valueinhealthjournal.com/article/S1098-3015(17)30063-9/fulltext
- Garrison, L. P., et al. (2018). “Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An ISPOR Special Task Force Report.” Value in Health, 21(1), 18-25. https://www.valueinhealthjournal.com/article/S1098-3015(17)30700-9/fulltext
- Drummond, M. F., et al. (2015). “Key Principles for the Improved Conduct of Health Technology Assessments for Resource Allocation Decisions.” International Journal of Technology Assessment in Health Care, 31(3), 105-115. https://www.researchgate.net/publication/5251069_Key_Principles_for_the_Improved_Conduct_of_Health_Technology_Assessments_for_Resource_Allocation_Decisions
- Goncalves, A., et al. (2020). “Generation and evaluation of synthetic patient data.” BMC Medical Research Methodology, 20, 108. https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-020-00977-1
- Chen, J., et al. (2021). “Synthetic data in health care: A narrative review.” PLOS Digital Health, 1(1). https://journals.plos.org/digitalhealth/article?id=10.1371/journal.pdig.0000082
- Walonoski, J., et al. (2018). “Synthea: An approach, method, and software mechanism for generating synthetic patients and the synthetic electronic health care record.” Journal of the American Medical Informatics Association, 25(3), 230-238. https://academic.oup.com/jamia/article/25/3/230/4098271
- Casey, J. A., et al. (2016). “Using electronic health records for population health research: a review of methods and applications.” Annual Review of Public Health, 37, 61-81. https://www.annualreviews.org/content/journals/10.1146/annurev-publhealth-032315-021353
- Herrett, E., et al. (2015). “Data Resource Profile: Clinical Practice Research Datalink (CPRD).” International Journal of Epidemiology, 44(3), 827-836. https://academic.oup.com/ije/article/44/3/827/634215
- Schneeweiss, S. (2014). “Learning from Big Health Care Data.” New England Journal of Medicine, 370, 2161-2163. https://www.nejm.org/doi/full/10.1056/NEJMp1401111
- Kantarjian, H., & Rajkumar, S. V. (2015). “Why are cancer drugs so expensive in the United States, and what are the solutions?” Mayo Clinic Proceedings, 90(4), 500-504. https://www.mayoclinicproceedings.org/article/S0025-6196(15)00184-5/fulltext
- Neumann, P. J., & Cohen, J. T. (2018). “QALYs in 2018—Advantages and Concerns.” JAMA, 319(24), 2473-2474. https://jamanetwork.com/journals/jama/article-abstract/2679209
- Makady, A., et al. (2017). “Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.” Value in Health, 20(4), 520-532. https://www.sciencedirect.com/science/article/pii/S1098301516341912